about cryptocurrency- Top Overview

Shenzhen Stock Exchange: The Shenzhen Stock Exchange, together with the Financial Office of Henan Provincial Party Committee, Henan Securities Regulatory Bureau and Zhengzhou Municipal Party Committee and Municipal Government, jointly held an industrial exchange meeting on "Shenzhen M&A Revitalizing Quality". This activity focused on the advantageous industries of high-end equipment manufacturing in Henan Province, discussed in depth the development characteristics of the industry and the main points of M&A investment, built an exchange platform, conveyed the concept of supervision, supported the integration of upstream and downstream of the industrial chain, strictly prevented insider trading in M&A and reorganization, and helped Henan develop new quality productivity according to local conditions. Next, Shenzhen Stock Exchange will continue to implement the requirements of "Six Articles on M&A" in accordance with the unified deployment of China Securities Regulatory Commission, adhere to the direction of marketization, adhere to the major strategy of serving the country, give full play to the role of the capital market as the main channel in enterprise M&A and reorganization, take various measures to support listed companies to standardize M&A and reorganization, promote the landing of high-quality cases, strengthen exchanges with market players, and strive to create a healthy and orderly market ecology.Shen Wanhongyuan: "Vigorously boosting consumption" is the first task of economic work next year. The Central Economic Work Conference was held in Beijing from December 11th to 12th. Shen Wanhongyuan released a research opinion saying that in this Central Economic Work Conference, it can be seen that boosting consumption has once again become the top priority in 2025. The "two innovations" and "two heavyweights" in 2024 are important points of economic work. "Two Innovations" means to promote a new round of large-scale equipment renewal and trade-in of consumer goods, and "Two Innovations" means to implement major national strategies and build safety capacity in key areas, and continue to pay attention to the efforts of fiscal policies including extra-long special national debt in this field.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

CITIC Jiantou: It maintains the "Buy" rating of Orrit, and its product line continues to expand and enrich. According to the research report of CITIC Jiantou Securities, Orrit (605116.SH) is one of the leading companies in the field of characteristic APIs in China. In recent years, the company's product line has been continuously expanded and enriched, which has promoted the continuous growth of revenue. At the same time, the company actively laid out potential areas, and at the current point of time, we think that we can see the company's follow-up multiple catalysis: 1) The preparation business continues to be heavy: the market development of diqu progesterone tablets continues to advance, and the estradiol/estradiol-diqu progesterone composite packaging tablets have been declared for listing. It is expected that the continuous enrichment of new pipelines for the follow-up preparation business will promote the company's performance growth. 2) Smegrutide API: The construction of fermentation workshop and synthesis workshop has been completed, and the expansion and release of new capacity will promote the good growth of API business. 3) Small nucleic acid business: The 100 kg commercial production line landed in September, 2004, opening up the space for subsequent growth. Maintain the "buy" rating.Ge Yu, former assistant general manager of China Xinbao Shandong Branch, was examined and investigated. The website of the State Supervision Committee of the Central Commission for Discipline Inspection reported on December 13th that according to the news of the Discipline Inspection and Supervision Team of the State Supervision Committee of the Central Commission for Discipline Inspection in China Export Credit Insurance Company and the Supervision Committee of Liaoning Provincial Commission for Discipline Inspection, Ge Yu, former member of the Party Committee and assistant general manager of Shandong Branch of China Export Credit Insurance Company, was suspected of serious violation of discipline and law. At present, he is being examined by the Discipline Inspection and Supervision Team of the State Supervision Committee of the Central Commission for Discipline Inspection in China Export Credit Insurance Company and supervised by the Supervision Committee of Dandong City, Liaoning Province.Hite Bio: Two drugs are planned to be selected for national centralized drug procurement. Hite Bio announced that the company participated in the tenth batch of national centralized drug procurement. According to the selected results released by the joint procurement, roxatidine acetate hydrochloride and pentoxifylline injection for injection of the company are selected for this centralized procurement. These two drugs are suitable for the treatment of upper gastrointestinal bleeding and peripheral arterial diseases respectively. The procurement cycle is from the date of implementation of the selected results to December 31, 2027, during which medical institutions will give priority to the use of selected drugs. The company obtained the Drug Registration Certificate of the above drugs in 2024, but it has not generated sales revenue this year. This election will help to enhance the brand influence of the company and have a positive impact on the company's development.

The Zhuhai earthquake did not meet the emergency response standard, so citizens need not worry too much. On December 13th, some Zhuhai citizens felt obvious vibration, and many people suspected that an earthquake had occurred. Some citizens felt the vibration during lunch break, and some people felt the building shaking in the office. On the afternoon of the 13th, the reporter called the Seismological Bureau of Guangdong Province, and the relevant staff responded that at about 1: 25 noon on December 13th, a magnitude 2.1 earthquake occurred in the urban area of Zhuhai, so citizens need not worry too much. Because the magnitude of the earthquake did not reach the preset emergency response standard, the relevant departments did not start the emergency response mechanism, so the earthquake quick report information was not released. The staff member said that the bureau is also concerned about the public's concern about the earthquake, and is currently conducting corresponding research and judgment, and will issue corresponding research and judgment opinions later. (Nanfang Daily)Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Baiyun Airport: The passenger throughput in the first November increased by 21.16% year-on-year. Baiyun Airport (600004) released the November production and operation data express on the evening of December 13th, and Baiyun Airport took 43,637 flights (sorties) in November, up by 12.94% year-on-year. Passenger throughput was 6,504,400 person-times, up by 19.94% year-on-year; The cargo and mail throughput was 212,100 tons, a year-on-year increase of 5.68%. Baiyun Airport took off and landed 465,983 sorties from January to November, up 12.05% year-on-year; The passenger throughput was 69.6674 million person-times, up by 21.16% year-on-year; The cargo and mail throughput was 2,161,300 tons, up 18.12% year-on-year.